STAT stories you may have missed

Atul Gawande, for all his professional accomplishments, was a newcomer at running a complex business venture like Haven. STAT looked at the halting progress at the company before his exit.

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock, writes STAT's Adam Feuerstein.

In a tale of two Mercks, the German company wins a court battle over its U.S. rival. Both companies use the name Merck in different parts of the world.

Although gliomas in children share some of the molecular mechanisms found in other types of cancers in adults, treatments for children have lagged behind.

A new analysis finds that 17 of the largest commercial health plans last year rarely preferred biosimilar versions of brand-name biologics when crafting coverage decisions.